Executive summary
Today's briefing converges on a single high-signal theme: metabolic and cellular health as the master lever for brain function, immune competence, muscle longevity, and biological age. Dr. Chris Palmer (McLean Hospital/Harvard) presents epidemiological and clinical trial data showing that standard psychiatric treatments achieve durable remission in as few as 4% of schizophrenia patients and 10% of depression patients over 12 years, and introduces a metabolic/mitochondrial framework—anchored by a ketogenic diet case study—as a candidate root-cause intervention. Simultaneously, Ben Greenfield's Episode 499 protocol stack, Dr. Berg's live Q&A, Fountain Life's Houston launch, and Justin Mares' biomarker-first framework all reinforce the same operational principle: measure first, remove inflammatory inputs second, then layer targeted interventions with trackable endpoints.
Key takeaways
- According to Dr. Chris Palmer (McLean Hospital/Harvard), only 10% of depression patients achieved durable remission over 12 years in a 400+ patient longitudinal study, and only 4% of schizophrenia patients achieved the composite outcome of symptom resolution, quality of life, and functional recovery in a 6,000+ patient cohort—framing the metabolic/mitochondrial model as a genuine mechanistic alternative worth tracking via ketone monitoring (target BHB ≥0.5 mmol/L) and a structured 1–10 daily mood/energy log.
- According to Ben Greenfield (Episode 499), creatine monohydrate at 10g on standard days and 15–20g on sleep-deprived or high cognitive-load days has strong human RCT support for working memory and processing speed improvements, with full cognitive saturation requiring 2–4 weeks—a substantially higher dose than the typical 3–5g athletic protocol and one of the most evidence-supported cognitive interventions available over-the-counter.
- Per Justin Mares (Kettle & Fire/TrueMed) and Fountain Life's internal data (cited by Dr. Peter Diamandis), any supplement protocol run without pre/post biomarker testing at 90-day intervals is uncontrolled experimentation; Function Health provides 190+ markers for approximately $500/year versus an estimated $7,000–$8,000 for equivalent conventional physician panels, and Fountain Life's operational data shows 3.4% of self-described healthy members had undetected cancers at intake—making diagnostic infrastructure the highest-leverage longevity investment available today.
THE DAILY OPTIMIZER
Today's briefing is unified by a convergent signal across five independent sources: the dominant failure mode in health optimization—whether you're managing mood, building muscle, preserving cognitive function, or extending healthspan—is unaddressed metabolic dysfunction at the cellular level. According to Dr. Chris Palmer (McLean Hospital, Harvard Medical School), only **10% of depression patients** achieved durable remission over a 12-year longitudinal study of 400+ patients at academic medical centers, and only **4% of schizophrenia patients** achieved the full triad of symptomatic remission, quality of life, and functional recovery in a 6,000+ patient cohort. These are not fringe statistics—they are the published outcomes of our current treatment paradigm. The antidote emerging across today's sources is not a single supplement but a systems-level approach: reduce cortisol and inflammatory load, restore mitochondrial signaling, measure what's actually happening in your blood and tissues, and build protocols around verified biomarker response. Ben Greenfield (Episode 499) identifies creatine monohydrate at **10g daily** as a cognitively underutilized molecule. Dr. Berg's Q&A establishes that magnesium glycinate at **600mg/day** is a foundational cofactor that most optimizers are under-dosing. Fountain Life's Houston launch data shows **3.4% of their self-described healthy members** had undetected cancers at intake. And Justin Mares (Kettle & Fire, TrueMed) argues that any supplement protocol run without pre/post biomarker testing at **90-day intervals** is uncontrolled experimentation. The full briefing below translates these signals into protocols you can implement this week.
DEEP DIVE: Brain Metabolism, Mitochondrial Function, and the Ketogenic Diet as a Psychiatric and Cognitive Intervention
Building on the foundational crisis data above, let's examine the mechanism Dr. Chris Palmer is developing—and what it means for your optimization stack today. **The Evidence Problem Driving the Search for New Mechanisms** According to Dr. Palmer's presentation at the Peterson Academy, the STAR*D trial—the largest depression treatment trial ever conducted, enrolling approximately 4,000 outpatients across four sequential treatment levels—is the benchmark for our current pharmacological approach. Using the trial's *original* remission criteria (which were changed mid-study), Dr. Palmer cites a reanalysis showing only **35% of patients achieved remission** across all four treatment levels. A 12-year longitudinal study of 400+ depression patients found subjects were symptomatically ill **59% of all weeks** across that period, with only **10%** achieving durable, lasting remission. For schizophrenia, a 6,000+ patient cohort tracked over 3 years found only **13% were able to work or function in society**, and only **4%** achieved the composite outcome of symptomatic remission, quality of life, and functional recovery simultaneously. Dr. Palmer's framing is precise: these are not access failures. They are **efficacy failures**. The drugs are not disease-modifying. **The Convergence Evidence: A Common Pathophysiology** Research cited by Dr. Palmer provides the mechanistic foundation for a new model: - Lahey (2012) examined all internalizing and externalizing mental disorders and identified a **general p-factor** common to all via neuroimaging, genetics, and risk factor cross-referencing. - Caspi & Moffitt (2018) extended this to all DSM diagnostic categories, concluding all psychiatric diagnoses appear to share a common pathophysiology. - Brandt et al. (year unspecified by Dr. Palmer) extended the finding to physical illnesses as well. The common thread, per Dr. Palmer's thesis: **brain energy metabolism dysfunction**, potentially rooted in **mitochondrial impairment**. **The Index Case: Ketogenic Diet and Schizoaffective Disorder** Dr. Palmer's n=1 pivot case involved a male patient with schizoaffective disorder under his care for **8 years**, actively psychotic daily on **three simultaneous antipsychotics at above FDA-approved doses**, sleeping approximately **16 hours/day**, and weighing **340 lbs** from iatrogenic medication-related weight gain. The ketogenic diet was initiated purely for weight management with no psychiatric intent. Timeline of response (per Dr. Palmer): - **~2 weeks:** Marked reduction in depression, spontaneous eye contact for the first time in 8 years, unprompted communication, humor—hallucinations and delusions still present - **~8 weeks:** Patient spontaneously reported voices beginning to resolve - **~10 weeks:** Patient voluntarily acknowledged the persecutory delusional system as no longer real and stated "maybe I have schizophrenia like everybody has been telling me" and that it appeared to be resolving This is a single case report—n=1, hypothesis-generating only, no causal proof established. But its mechanistic implications are significant: if the ketogenic diet's primary action is metabolic—shifting substrate from glucose to ketone bodies (beta-hydroxybutyrate, BHB), reducing neuroinflammation, supporting mitochondrial efficiency—then brain energy metabolism is a genuine therapeutic target. **Actionable Protocol: Implementing Ketogenic Metabolic Intervention** For optimizers interested in exploring the metabolic-psychiatric connection as either a cognitive enhancer or a mood stabilizer, here is the tracking framework: 1. **Baseline assessment (Week 0):** Use Dr. Palmer's 1–10 self-rating scales for both mental health and metabolic health. Record fasting glucose, fasting insulin, HbA1c, and a full lipid panel (including ApoB per Justin Mares' recommendation on this same broadcast date). 2. **Dietary protocol:** Standard ketogenic ratios—low carbohydrate (target **≤50g/day** per Dr. Berg's concurrent recommendation), moderate protein, high fat. This is the composition used in Dr. Palmer's index case, though exact macros were not specified in Lecture 1. 3. **Ketone monitoring:** Blood beta-hydroxybutyrate (BHB) via fingerstick meter. Target nutritional ketosis at **≥0.5 mmol/L**; optimal range for neurological benefit commonly cited as **1.0–3.0 mmol/L**. Also track the glucose-ketone index (GKI) as a composite metabolic signal. 4. **Electrolyte support (critical during weeks 1–3):** Per Dr. Berg's concurrent protocol, magnesium glycinate **600mg/day**, potassium **1,000mg x4 doses/day** (spread to prevent urinary loss), and sodium titrated to thirst. Dr. Berg explicitly states that magnesium and Vitamin D are bidirectionally dependent—neither functions optimally without the other. 5. **Timeline for psychiatric or cognitive signal:** Dr. Palmer's case showed mood/cognitive signals at approximately **2 weeks** and psychotic symptom resolution at **8–10 weeks**. For subclinical cognitive optimization targets, expect a **4–8 week** window before drawing conclusions. 6. **Daily tracking stack:** Morning HRV (Oura Ring, WHOOP, or Polar H10), sleep architecture (total sleep time, REM and deep sleep percentages), daily 1–10 mood/energy/focus/anxiety ratings, and weekly body weight. 7. **Safety rails:** Never adjust psychiatric medications without prescriber supervision. Monitor serum calcium (not Vitamin D alone) as the toxicity proxy for high-dose D3 co-administration. Full lipid panel at baseline and 3-month follow-up—ketogenic diets can substantially alter LDL, HDL, and triglyceride profiles. Contraindications include pyruvate carboxylase deficiency, porphyria, and fat oxidation disorders (LCAD, MCAD deficiencies). The mechanistic "why": the ketogenic state shifts neuronal energy substrate from glucose to ketone bodies, which enter the TCA cycle downstream of the glycolytic bottleneck implicated in metabolic dysfunction. BHB also acts as an HDAC inhibitor with epigenetic effects, reduces NLRP3 inflammasome activation (a key neuroinflammation pathway), and may support mitochondrial biogenesis. Dr. Palmer's subsequent lectures (flagged for future protocol updates) will address these mechanisms in full.
METRICS & MEASUREMENT
Across today's sources, several specific, trackable biomarkers emerge as the highest-yield monitoring targets for this protocol cluster. According to Justin Mares (Kettle & Fire, TrueMed), biomarker testing through platforms like Function Health (~$500/year for 190+ markers) at **90-day intervals** is the minimum viable measurement cadence for any intervention. He specifically prioritizes **ApoB** over standard LDL as the cardiovascular risk marker, alongside fasting insulin, HbA1c, and a full thyroid panel. For the metabolic-brain intervention: track fasting glucose and GKI (glucose-ketone index) alongside blood BHB. A GKI below 3.0 indicates therapeutic ketosis; below 1.0 indicates deep therapeutic range used in oncological and neurological protocols. For immune competence (per the physicians on the drsuneeldhand source): serum **25(OH)D** every 3–6 months targeting **40–60 ng/mL**; **hsCRP** quarterly targeting **<1.0 mg/L**. For strength training progress: grip strength via dynamometer (a validated longevity biomarker at ~$20–40) monthly, alongside HRV trending as a daily cortisol-load proxy. Meaningful change thresholds: a **5-point shift in GKI**, a **10 ng/mL increase in 25(OH)D**, or a **0.3ms consistent increase in morning HRV** over 4 weeks each represent protocol-responsive signals worth documenting.
THE LONGEVITY TOOLKIT
Today's toolkit spotlight: **Fountain Life's multi-cancer liquid biopsy panel**, cited at the Houston center launch by Dr. Peter Diamandis and Dr. Dawn Musalem (Chief Medical Officer, Mayo Clinic-trained). According to Fountain Life's internal operational data cited by Diamandis, approximately **3.4% of members presenting for their first Fountain Life intake** had a cancer they were unaware of—a notable finding given this is a self-selected, health-conscious demographic who presumably believed themselves healthy. The mechanism: a single blood draw screens simultaneously for **50 different cancer types** via circulating tumor DNA (ctDNA) detection. This is distinct from and complementary to full-body MRI (structural imaging) and AI-powered coronary CT angiography (CCTA) for cardiovascular plaque burden. The survival rate delta that frames its value, per data cited by Tony Robbins (co-founder) from the American Cancer Society: **Stage 4 diagnosis carries approximately a 20% survival rate; Stage 1 diagnosis carries a 99.8% survival rate**. The entire value proposition of early detection lives in that gap. For optimizers not in a Fountain Life market (currently 5 US centers): liquid biopsy cancer panels and CCTA are increasingly accessible through direct-access diagnostics companies and concierge medicine practices. This is the diagnostic layer that no supplement stack can substitute for.
FUEL & RECOVERY
Building on the metabolic protocols above, today's fuel focus is the **pre-workout collagen timing protocol** highlighted by Dr. Berg in his April 17, 2026 Q&A session—a simple but mechanistically grounded intervention that most optimizers are missing. According to Dr. Berg, collagen powder consumed in isolation by a sedentary person produces negligible structural benefit—he characterizes it as "expensive urine" without the mechanical loading signal. The intervention: consume collagen **30–60 minutes before training** to significantly improve connective tissue incorporation. The mechanism: circulating amino acids (primarily glycine, proline, and hydroxyproline) are available during the mechanical loading window when fibroblasts are actively remodeling collagen matrices in tendons, ligaments, and cartilage. Stack this with the foundational micronutrient triad Dr. Berg identifies as non-negotiable for muscle and connective tissue function: **magnesium glycinate** (you cannot build muscle without magnesium, per Dr. Berg), **zinc** (critical for testosterone production and androgenic muscle signaling), and **potassium** (required for neuromuscular junction function). Dr. Eric Berg also notes that bone density loss in sedentary or bedridden individuals reaches **1–2% per week**—approximately **52 times faster** than the roughly 1% per 8–12 months seen in menopause-related decline—reinforcing that movement itself is the foundational recovery and structural maintenance tool, not supplementation alone.
Sources
- Peterson Academy / Dr. Chris Palmer — Brain Metabolism & Mental Health Lecture 1 (via JordanBPeterson)
- Chris Williamson — Tour Diary: Australia, Beers & Chris Hemsworth
- Dr. Eric Berg DC — STOP Doing THIS If You Want to Build Muscle
- Ben Greenfield Life — The Peptide Stack That Actually Grows Hair (Episode 499)
- drsuneeldhand — 3 Natural IMMUNE BOOSTS Doctors Don't Tell You
- Fountain Life — Houston Opening
- Dr. Eric Berg DC — The Dr. Berg Show LIVE, April 17, 2026
- My First Million — The Healthcare Revolution Is Just Getting Started (Justin Mares)
- Chris Williamson — 'Demonising Men Is Not A Good Strategy' (Richard Reeves) [no biohackable content extracted]